Anti-mycobacterial peptides: From human to phage

Cellular Physiology and Biochemistry

Volumn 35, Issue 2, 2015, Pages 452-466

  Teng, Tieshan ^a,b   Liu, Jiafa ^c   Wei, Hongping ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Hubei Institute for Infectious Disease Control and Prevention   (China)

Author keywords

Anti mycobacterial peptides; Mycobacterial; Tuberculosis

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN; E50 52; GRANULYSIN; HCL2 PROTEIN; HEPCIDIN; LACTICIN 3147; LASSOMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; RIBONUCLEASE; UBIQUITIN; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; CHANNEL GATING; DRUG MECHANISM; EXTRACTION; HOST CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MYCOBACTERIOPHAGE; PRIORITY JOURNAL; REVIEW; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS; PROKARYOTA;

ANTIMICROBIAL CATIONIC PEPTIDES; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84921883428     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369711     Document Type: Review

References (124)

1. Osborne R: First novel anti-tuberculosis drug in 40 years. Nat Biotechnol 2013; 31: 89-91.
2. Waghu FH, Gopi L, Barai RS, Ramteke P, Nizami B, Idicula-Thomas S: Camp: Collection of sequences and structures of antimicrobial peptides. Nucleic Acids Res 2014; 42: D1154-1158.
3. Zhao X, Wu H, Lu H, Li G, Huang Q: Lamp: A database linking antimicrobial peptides. PLoS One 2013; 8: e66557.
4. Mendez-Samperio P: The human cathelicidin hcap18/ll-37: A multifunctional peptide involved in mycobacterial infections. Peptides 2010; 31: 1791-1798.
5. Sorensen O, Cowland JB, Askaa J, Borregaard N: An elisa for hcap-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 1997; 206: 53-59.
6. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N: Human cathelicidin, hcap-18, is processed to the antimicrobial peptide ll-37 by extracellular cleavage with proteinase 3. Blood 2001; 97: 3951-3959.
7. Liu PT, Stenger S, Tang DH, Modlin RL: Cutting edge: Vitamin d-mediated human antimicrobial activity against mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179: 2060-2063.
8. Sonawane A, Santos JC, Mishra BB, Jena P, Progida C, Sorensen OE, Gallo R, Appelberg R, Griffiths G: Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell Microbiol 2011; 13: 1601-1617.
9. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, Davidson RN, Sorensen OE, Kampmann B, Griffiths CJ, Wilkinson RJ: Ifn-gamma-and tnf-independent vitamin d-inducible human suppression of mycobacteria: The role of cathelicidin ll-37. J Immunol 2007; 178: 7190-7198.
10. Yamshchikov AV, Kurbatova EV, Kumari M, Blumberg HM, Ziegler TR, Ray SM, Tangpricha V: Vitamin d status and antimicrobial peptide cathelicidin (ll-37) concentrations in patients with active pulmonary tuberculosis. Am J Clin Nutr 2010; 92: 603-611.
11. Gorr SU, Abdolhosseini M: Antimicrobial peptides and periodontal disease. J Clin Periodontol 2011; 38: S126-141.
12. Jiang Z, Higgins MP, Whitehurst J, Kisich KO, Voskuil MI, Hodges RS: Anti-tuberculosis activity of alpha-helical antimicrobial peptides: De novo designed l-and d-enantiomers versus l-and d-ll-37. Protein Pept Lett 2011; 18: 241-252.
13. Nagaoka I, Hirota S, Niyonsaba F, Hirata M, Adachi Y, Tamura H, Tanaka S, Heumann D: Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin cap18/ll-37-Derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol 2002; 9: 972-982.
14. Mohanty S, Jena P, Mehta R, Pati R, Banerjee B, Patil S, Sonawane A: Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages. Antimicrob Agents Ch 2013; 57: 3688-3698.
15. McGrath DM, Barbu EM, Driessen WH, Lasco TM, Tarrand JJ, Okhuysen PC, Kontoyiannis DP, Sidman RL, Pasqualini R, Arap W: Mechanism of action and initial evaluation of a membrane active all-d-enantiomer antimicrobial peptidomimetic. Proc Natl Acad Sci U S A 2013; 110: 3477-3482.
16. Carmona G, Rodriguez A, Juarez D, Corzo G, Villegas E: Improved protease stability of the antimicrobial peptide pin2 substituted with d-amino acids. Protein J 2013; 32: 456-466.
17. Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R: D-amino acids trigger biofilm disassembly. Science 2010; 328: 627-629.
18. Vandamme D, Landuyt B, Luyten W, Schoofs L: A comprehensive summary of ll-37, the factotum human cathelicidin peptide. Cell Immunol 2012; 280: 22-35.
19. Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D: Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as immune adjuVant. J Immunol 2005; 174: 6257-6265.
20. Cho J, Hwang IS, Choi H, Hwang JH, Hwang JS, Lee DG: The novel biological action of antimicrobial peptides via apoptosis induction. J Microbiol Biotechnol 2012; 22: 1457-1466.
21. Buchau AS, Morizane S, Trowbridge J, Schauber J, Kotol P, Bui JD, Gallo RL: The host defense peptide cathelicidin is required for nk cell-mediated suppression of tumor growth. J Immunol 2010; 184: 369-378.
22. Liu PT, Modlin RL: Human macrophage host defense against mycobacterium tuberculosis. Curr Opin Immunol 2008; 20: 371-376.
23. Kalita A, Verma I, Khuller GK: Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis 2004; 190: 1476-1480.
24. Sharma S, Verma I, Khuller GK: Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Ch 2001; 45: 639-640.
25. Sharma S, Khuller GK: DNA as the intracellular secondary target for antibacterial action of human neutrophil peptide-i against mycobacterium tuberculosis h37ra. Curr Microbiol 2001; 43: 74-76.
26. Sharma S, Verma I, Khuller GK: Biochemical interaction of human neutrophil peptide-1 with mycobacterium tuberculosis h37ra. Arch Microbiol 1999; 171: 338-342.
27. Sharma S, Verma I, Khuller GK: Antibacterial activity of human neutrophil peptide-1 against mycobacterium tuberculosis h37rv: In vitro and ex vivo study. EurRespir J 2000; 16: 112-117.
28. Zhu LM, Liu CH, Chen P, Dai AG, Li CX, Xiao K, Chen Y, Cao J, Chen YR: Multidrug-resistant tuberculosis is associated with low plasma concentrations of human neutrophil peptides 1-3. Int J Tuberc Lung D 2011; 15: 369-374.
29. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J: Human beta-defensins. Cell Mol Life Sci 2006; 63: 1294-1313.
30. Gonzalez-Curiel I, Castaneda-Delgado J, Lopez-Lopez N, Araujo Z, Hernandez-Pando R, Gandara-Jasso B, Macias-Segura N, Enciso-Moreno A, Rivas-Santiago B: Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus. Hum Immunol 2011; 72: 656-662.
31. Kisich KO, Heifets L, Higgins M, Diamond G: Antimycobacterial agent based on mrna encoding human beta-defensin 2 enables primary macrophages to restrict growth of mycobacterium tuberculosis. Infect Immun 2001; 69: 2692-2699.
32. Rivas-Santiago CE, Rivas-Santiago B, Leon DA, Castaneda-Delgado J, Pando RH: Induction of beta-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis. Clin Exp Immunol 2011; 164: 80-89.
33. Rivas-Santiago B, CerVantes-Villagrana A, Sada E, Hernandez-Pando R: Expression of beta defensin 2 in experimental pulmonary tuberculosis: Tentative approach for vaccine development. Arch Med Res 2012; 43: 324-328.
34. Mendez-Samperio P: Recent adVances in the field of antimicrobial peptides in inflammatory diseases. Adv Biomed Res 2013; 2: 50.
35. Ernst CM, Peschel A: Broad-spectrum antimicrobial peptide resistance by mprf-mediated aminoacylation and flipping of phospholipids. Mol Microbiol 2011; 80: 290-299.
36. Pitabut N, Sakurada S, Tanaka T, Ridruechai C, Tanuma J, Aoki T, Kantipong P, Piyaworawong S, Kobayashi N, Dhepakson P, Yanai H, Yamada N, Oka S, Okada M, Khusmith S, Keicho N: Potential function of granulysin, other related effector molecules and lymphocyte subsets in patients with tb and hiv/tb coinfection. Int J Med Sci 2013; 10: 1003-1014.
37. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL: An antimicrobial activity of cytolytic t cells mediated by granulysin. Science 1998; 282: 121-125.
38. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, Takao K, Kishigami C, Nishimatsu S, Sekine Y, Inoue Y, Matsumoto M, McMurray DN, De la Cruz EC, Tan EV, Abalos RM, Burgos JA, SaunDerson P, Sakatani M: Novel therapeutic vaccine: Granulysin and new DNA vaccine against tuberculosis. Hum Vaccin 2011; 7: S60-67.
39. Mueller H, Fae KC, Magdorf K, Ganoza CA, Wahn U, Guhlich U, Feiterna-Sperling C, Kaufmann SHE: Granulysin-expressing cd4 (+) t cells as candidate immune marker for tuberculosis during childhood and adolescence. PLoS One 2011; 6: e29367.
40. Andreu D, Carreno C, Linde C, Boman HG, AnDersson M: Identification of an anti-mycobacterial domain in nk-lysin and granulysin. Biochem J 1999; 344 Pt 3: 845-849.
41. Wang Z, Choice E, Kaspar A, Hanson D, Okada S, Lyu SC, Krensky AM, Clayberger C: Bactericidal and tumoricidal activities of synthetic peptides Derived from granulysin. J Immunol 2000; 165: 1486-1490.
42. Toro JC, Hoffner S, Linde C, AnDersson M, AnDersson J, Grundstrom S: Enhanced susceptibility of multidrug resistant strains of mycobacterium tuberculosis to granulysin peptides correlates with a reduced fitness phenotype. Microbes Infect 2006; 8: 1985-1993.
43. Purdy GE, Russell DG: Lysosomal ubiquitin and the demise of mycobacterium tuberculosis. Cell Microbiol 2007; 9: 2768-2774.
44. Alonso S, Pethe K, Russell DG, Purdy GE: Lysosomal killing of mycobacterium mediated by ubiquitin-Derived peptides is enhanced by autophagy. P Natl Acad Sci USA 2007; 104: 6031-6036.
45. Wang QM, Kang L, Wang XH: Improved cellular immune response elicited by a ubiquitin-fused esat-6 DNA vaccine against mycobacterium tuberculosis. Microbiol Immunol 2009; 53: 384-390.
46. Wang QM, Tang Y, Lei Ch X, Shi FZ, Liu QH: Enhanced cellular immune response elicited by a DNA vaccine fused with ub against mycobacterium tuberculosis. Scand J Immunol 2012; 76: 123-130.
47. Wang Q, Lei C, Wan H, Liu Q: Improved cellular immune response elicited by a ubiquitin-fused DNA vaccine against mycobacterium tuberculosis. DNA Cell Biol 2012; 31: 489-495.
48. Kieffer AE, Goumon Y, Ruh O, Chasserot-Golaz S, Nullans G, Gasnier C, Aunis D, Metz-Boutigue MH: The n-and c-terminal fragments of ubiquitin are important for the antimicrobial activities. FASEB J 2003; 17: 776-778.
49. Foss MH, Powers KM, Purdy GE: Structural and functional characterization of mycobactericidal ubiquitin-Derived peptides in model and bacterial membranes. Biochemistry 2012; 51: 9922-9929.
50. Purdy GE, NieDerweis M, Russell DG: Decreased outer membrane permeability protects mycobacteria from killing by ubiquitin-Derived peptides. Mol Microbiol 2009; 73: 844-857.
51. Daugherty A, Powers KM, Standley MS, Kim CS, Purdy GE: Mycobacterium smegmatis roxy is a repressor of oxys and contributes to resistance to oxidative stress and bactericidal ubiquitin-Derived peptides. J Bacteriol 2011; 193: 6824-6833.
52. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, DonoVan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
53. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044.
54. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP: Expression and localization of hepcidin in macrophages: A role in host defense against tuberculosis. J Leukoc Biol 2007; 82: 934-945.
55. Sow FB, Nandakumar S, Velu V, Kellar KL, Schlesinger LS, Amara RR, Lafuse WP, Shinnick TM, Sable SB: Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin. Tuberculosis (Edinb) 2011; 91: 314-321.
56. Layoun A, Santos MM: Bacterial cell wall constituents induce hepcidin expression in macrophages through myd88 signaling. Inflammation 2012; 35: 1500-1506.
57. Pulido D, Torrent M, Andreu D, Nogues MV, Boix E: Two human host defense ribonucleases against mycobacteria, the eosinophil cationic protein (rnase 3) and rnase 7. Antimicrob Agents Chemother 2013; 57: 3797-3805.
58. Yang H, Chen HZ, Liu ZH, Ma H, Qin LH, Jin RL, Zheng RJ, Feng YH, Cui ZL, Wang J, Liu JM, Hu ZY: A novel b-cell epitope identified within mycobacterium tuberculosis cfp10/esat-6 protein. PLoS One 2013; 8: e52848.
59. Meher AK, Bal NC, Chary KV, Arora A: Mycobacterium tuberculosis h37rv esat-6-cfp-10 complex formation confers thermodynamic and biochemical stability. FEBS J 2006; 273: 1445-1462.
60. Chatterjee S, Dwivedi VP, Singh Y, Siddiqui I, Sharma P, Van Kaer L, Chattopadhyay D, Das G: Early secreted antigen esat-6 of mycobacterium tuberculosis promotes protective t helper 17 cell responses in a toll-like receptor-2-dependent manner. PLoS Pathog 2011; 7: e1002378.
61. Cotter PD, Hill C, Ross RP: Bacterial lantibiotics: Strategies to improve therapeutic potential. Curr Protein Pept Sci 2005; 6: 61-75.
62. Carroll J, Draper LA, O'Connor PM, Coffey A, Hill C, Ross RP, Cotter PD, O'Mahony J: Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents 2010; 36: 132-136.
63. Morgan SM, O'Connor P M, Cotter PD, Ross RP, Hill C: Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother 2005; 49: 2606-2611.
64. Draper LA, Cotter PD, Hill C, Ross RP: The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit gram negative bacteria. BMC Microbiol 2013; 13: 212.
65. Cotter PD, O'Connor PM, Draper LA, Lawton EM, Deegan LH, Hill C, Ross RP: Posttranslational conversion of l-serines to d-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147. Proc Natl Acad Sci U S A 2005; 102: 18584-18589.
66. Suda S, Lawton EM, Wistuba D, Cotter PD, Hill C, Ross RP: Homologues and bioengineered Derivatives of ltnj vary in ability to form d-alanine in the lantibiotic lacticin 3147. J Bacteriol 2012; 194: 708-714.
67. Islam MR, Nagao J, Zendo T, Sonomoto K: Antimicrobial mechanism of lantibiotics. Biochem Soc Trans 2012; 40: 1528-1533.
68. Asaduzzaman SM, Sonomoto K: Lantibiotics: Diverse activities and unique modes of action. J Biosci Bioeng 2009; 107: 475-487.
69. Martin NI, Breukink E: Expanding role of lipid ii as a target for lantibiotics. Future Microbiol 2007; 2: 513-525.
70. Draper LA, Grainger K, Deegan LH, Cotter PD, Hill C, Ross RP: Cross-immunity and immune mimicry as mechanisms of resistance to the lantibiotic lacticin 3147. Mol Microbiol 2009; 71: 1043-1054.
71. Sosunov V, Mischenko V, Eruslanov B, Svetoch E, Shakina Y, Stern N, Majorov K, Sorokoumova G, Selishcheva A, Apt A: Antimycobacterial activity of bacteriocins and their complexes with liposomes. J Antimicrob Chemoth 2007; 59: 919-925.
72. Gavrish E, Sit CS, Cao SG, Kandror O, Spoering A, Peoples A, Ling L, Fetterman A, Hughes D, Bissell A, Torrey H, Akopian T, Mueller A, Epstein S, Goldberg A, Clardy J, Lewis K: Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the atp-dependent protease clpc1p1p2. Chem Biol 2014; 21: 509-518.
73. Akopian T, Kandror O, Raju RM, UnniKrishnan M, Rubin EJ, Goldberg AL: The active clpp protease from m. Tuberculosis is a complex composed of a heptameric clpp1 and a clpp2 ring. Embo J 2012; 31: 1529-1541.
74. Sassi M, Bebeacua C, Drancourt M, Cambillau C: The first structure of a mycobacteriophage, the mycobacterium abscessus subsp. Bolletii phage araucaria. J Virol 2013; 87: 8099-8109.
75. Wei L, Wu J, Liu H, Yang HL, Rong MQ, Li DS, Zhang PH, Han JY, Lai R: A mycobacteriophage-Derived trehalose-6, 6 '-dimycolate-binding peptide containing both antimycobacterial and anti-inflammatory abilities. Faseb J 2013; 27: 3067-3077.
76. Fenton M, Keary R, McAuliffe O, Ross RP, O'Mahony J, Coffey A: Bacteriophage-Derived peptidase chap (k) eliminates and prevents staphylococcal biofilms. Int J Microbiol 2013; 2013: 625341.
77. Horgan M, O'Flynn G, Garry J, Cooney J, Coffey A, Fitzgerald GF, Ross RP, McAuliffe O: Phage lysin lysk can be truncated to its chap domain and retain lytic activity against live antibiotic-resistant staphylococci. Appl Environ Microb 2009; 75: 872-874.
78. Yang H, Wang DB, Dong Q, Zhang Z, Cui Z, Deng J, Yu J, Zhang XE, Wei H: Existence of separate domains in lysin plyg for recognizing bacillus anthracis spores and vegetative cells. Antimicrob Agents Chemother 2012; 56: 5031-5039.
79. Loessner MJ: Bacteriophage endolysins-current state of research and applications. Curr Opin Microbiol 2005; 8: 480-487.
80. Wan Y, Han J, Fan G, Zhang Z, Gong T, Sun X: Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity. Biomaterials 2013; 34: 3020-3030.
81. Lofton H, Pranting M, Thulin E, AnDersson DI: Mechanisms and fitness costs of resistance to antimicrobial peptides ll-37, cny100hl and wheat germ histones. PLoS One 2013; 8: e68875.
82. Ryan L, Lamarre B, Diu T, Ravi J, Judge PJ, Temple A, Carr M, Cerasoli E, Su B, Jenkinson HF, Martyna G, Crain J, Watts A, Ryadnov MG: Anti-antimicrobial peptides: Folding-mediated host defense antagonists. J Biol Chem 2013; 288: 20162-20172.
83. Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C, Ross RP: Bioengineered nisin a Derivatives with enhanced activity against both gram positive and gram negative pathogens. PLoS One 2012; 7.
84. Falciani C, Lozzi L, Pollini S, Luca V, Carnicelli V, Brunetti J, Lelli B, Bindi S, Scali S, Di Giulio A, Rossolini GM, Mangoni ML, Bracci L, Pini A: Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens. PLoS One 2012; 7.
85. Wang Y, Ke XY, Khara JS, Bahety P, Liu SQ, Seow SV, Yang YY, Ee PLR: Synthetic modifications of the immunomodulating peptide thymopentin to confer anti-mycobacterial activity. Biomaterials 2014; 35: 3102-3109.
86. Munk JK, Ritz C, Fliedner FP, Frimodt-Moller N, Hansen PR: Novel method to identify the optimal antimicrobial peptide in a combination matrix, using anoplin as an example. Antimicrob Agents Chemother 2014; 58: 1063-1070.
87. SaraVanan R, Li X, Lim K, Mohanram H, Peng L, Mishra B, Basu A, Lee JM, Bhattacharjya S, Leong SS: Design of short membrane selective antimicrobial peptides containing tryptophan and arginine residues for improved activity, salt-resistance, and biocompatibility. Biotechnol Bioeng 2014; 111: 37-49.
88. Dangel A, Ackermann N, Abdel-Hadi O, Maier R, OnDer K, Francois P, Muller CW, Pane-Farre J, Engelmann S, Schrenzel J, Heesemann J, LinDermayr C: A de novo-designed antimicrobial peptide with activity against multiresistant staphylococcus aureus acting on rsbw kinase. FASEB J 2013; 27: 4476-4488.
89. Mooney C, Haslam NJ, Pollastri G, Shields DC: Towards the improved discovery and design of functional peptides: Common features of diverse classes permit generalized prediction of bioactivity. PLoS One 2012; 7: e45012.
90. Hilpert K, Volkmer-Engert R, Walter T, Hancock REW: High-throughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 2005; 23: 1008-1012.
91. Guralp SA, Murgha YE, Rouillard JM, Gulari E: From design to screening: A new antimicrobial peptide discovery pipeline. PLoS One 2013; 8: e59305.
92. Hassan M, Kjos M, Nes IF, Diep DB, Lotfipour F: Natural antimicrobial peptides from bacteria: Characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol 2012; 113: 723-736.
93. Yan JX, Wang KR, Dang W, Chen R, Xie JQ, Zhang BZ, Song JJ, Wang R: Two hits are better than one: Membrane-active and DNA binding-related double-action mechanism of nk-18, a novel antimicrobial peptide Derived from mammalian nk-lysin. Antimicrob Agents Ch 2013; 57: 220-228.
94. Devocelle M: Targeted antimicrobial peptides. Front Immunol 2012; 3: 309.
95. Li Y, Xiang Q, Zhang Q, Huang Y, Su Z: Overview on the recent study of antimicrobial peptides: Origins, functions, relative mechanisms and application. Peptides 2012; 37: 207-215.
96. Zhao YY, Tian Y, Cui Y, Liu WW, Ma WS, Jiang XY: Small molecule-capped gold nanoparticles as potent antibacterial agents that target gram-negative bacteria. J Am Chem Soc 2010; 132: 12349-12356.
97. Mohanty S, Jena P, Mehta R, Pati R, Banerjee B, Patil S, Sonawane A: Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages. Antimicrob Agents Chemother 2013; 57: 3688-3698.
98. Arnusch CJ, Pieters RJ, Breukink E: Enhanced membrane pore formation through high-affinity targeted antimicrobial peptides. PLoS One 2012; 7.
99. Filatova LY, DonoVan DM, Becker SC, Lebedev DN, Priyma AD, Koudriachova HV, Kabanov AV, Klyachko NL: Physicochemical characterization of the staphylolytic lysk enzyme in complexes with polycationic polymers as a potent antimicrobial. Biochimie 2013; 95: 1689-1696.
100. Joshi S, Bisht GS, Rawat DS, Maiti S, Pasha S: Comparative mode of action of novel hybrid peptide cs-1a and its rearranged amphipathic analogue cs-2a. FEBS J 2012; 279: 3776-3790.
101. Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman J, Noinaj N, Kirby TL, HenDerson JP, Steven AC, Hinnebusch BJ, Buchanan SK: Structural engineering of a phage lysin that targets gram-negative pathogens. P Natl Acad Sci USA 2012; 109: 9857-9862.
102. Patzer SI, Albrecht R, Braun V, Zeth K: Structural and mechanistic studies of pesticin, a bacterial homolog of phage lysozymes. J Biol Chem 2012; 287: 23381-23396.
103. Singh D, Qi RS, Jordan JL, Mateo LS, Kao CC: The human antimicrobial peptide ll-37, but not the mouse ortholog, mcramp, can stimulate signaling by poly (i: C) through a fprl1-dependent pathway. J Biol Chem 2013; 288: 8258-8268.
104. Llamas-Gonzalez YY, Pedroza-Roldan C, Cortes-Serna MB, Marquez-Aguirre AL, Galvez-Gastelum FJ, Flores-Valdez MA: The synthetic cathelicidin hhc-10 inhibits mycobacterium bovis bcg in vitro and in c57bl/6 mice. Microb Drug Resist 2013; 19: 124-129.
105. Yamshchikov AV, Kurbatova EV, Kumari M, Blumberg HM, Ziegler TR, Ray SM, Tangpricha V: Vitamin d status and antimicrobial peptide cathelicidin (ll-37) concentrations in patients with active pulmonary tuberculosis. Am J Clin Nutr 2010; 92: 603-611.
106. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, Davidson RN, Sorensen OE, Kampmann B, Griffiths CJ, Wilkinson RJ: Ifn-gamma-and tnf-independent vitamin d-inducible human suppression of mycobacteria: The role of cathelicidin ll-37 (vol 178, pg 7190, 2007). J Immunol 2007; 179: 8569-8570.
107. Rivas-Santiago B, Rivas Santiago CE, Castaneda-Delgado JE, Leon-Contreras JC, Hancock RE, Hernandez-Pando R: Activity of ll-37, cramp and antimicrobial peptide-Derived compounds e2, e6 and cp26 against mycobacterium tuberculosis. Int J Antimicrob Agents 2013; 41: 143-148.
108. Rivas-Santiago B, Hernandez-Pando R, Carranza C, Juarez E, Contreras JL, Aguilar-Leon D, Torres M, Sada E: Expression of cathelicidin ll-37 during mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immun 2008; 76: 935-941.
109. Mohanty S, Jena P, Mehta R, Pati R, Banerjee B, Patil S, Sonawane A: Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages. Antimicrob Agents Chemother 2013; 57: 3688-3698.
110. Yacoby I, Benhar I: Targeted anti bacterial therapy. Infect Disord Drug Targets 2007; 7: 221-229.
111. SchneiDer JJ, Unholzer A, Schaller M, Schafer-Korting M, Korting HC: Human defensins. J Mol Med (Berl) 2005; 83: 587-595.
112. Samuchiwal SK, Tousif S, Singh DK, Kumar A, Ghosh A, Bhalla K, Prakash P, Kumar S, Bhattacharyya M, Moodley P, Das G, Ranganathan A: A peptide fragment from the human cox3 protein disrupts association of mycobacterium tuberculosis virulence proteins esat-6 and cfp10, inhibits mycobacterial growth and mounts protective immune response. BMC Infect Dis 2014; 14: 355.
113. Santos P, Gordillo A, Osses L, Salazar LM, Soto CY: Effect of antimicrobial peptides on atpase activity and proton pumping in plasma membrane vesicles obtained from mycobacteria. Peptides 2012; 36: 121-128.
114. Duclohier H, Molle G, Spach G: Antimicrobial peptide magainin-i from xenopus skin forms anion-permeable channels in planar lipid bilayers. Biophys J 1989; 56: 1017-1021.
115. Kieffer AE, Goumon Y, Ruh O, Chasserot-Golaz S, Nullans G, Gasnier C, Aunis D, Metz-Boutigue MH: The n-and c-terminal fragments of ubiquitin are important for the antimicrobial activities. Faseb J 2003; 17: 776-778.
116. Spencer JD, SchwaDerer AL, DiRosario JD, McHugh KM, McGillivary G, Justice SS, Carpenter AR, Baker PB, HarDer J, Hains DS: Ribonuclease 7 is a potent antimicrobial peptide within the human urinary tract. Kidney Int 2011; 80: 175-181.
117. Sow FB, Alvarez GR, Gross RP, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP: Role of stat1, nf-kappa b, and c/ebp beta in the macrophage transcriptional regulation of hepcidin by mycobacterial infection and ifn-gamma. J Leukocyte Biol 2009; 86: 1247-1258.
118. Barthe C, Hocquellet A, Garbay B: Bacteriostatic activity of the proregion of human hepcidin. Protein Pept Lett 2011; 18: 36-40.
119. Silva T, Magalhaes B, Maia S, Gomes P, Nazmi K, Bolscher JG, Rodrigues PN, Bastos M, Gomes MS: Killing of mycobacterium avium by lactoferricin peptides: Improved activity of arginine-and d-amino-acid-containing molecules. Antimicrob Agents Chemother 2014; 58: 3461-3467.
120. Carroll J, Field D, O'Connor PM, Cotter PD, Coffey A, Hill C, Ross RP, O'Mahony J: Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Bioeng Bugs 2010; 1: 408-412.
121. Morgan SM, O'Connor PM, Cotter PD, Ross RP, Hill C: Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Ch 2005; 49: 2606-2611.
122. Ryan MP, Jack RW, Josten M, Sahl HG, Jung G, Ross RP, Hill C: Extensive post-translational modification, including serine to d-alanine conversion, in the two-component lantibiotic, lacticin 3147. J Biol Chem 1999; 274: 37544-37550.
123. Kapoor R, Eimerman PR, Hardy JW, Cirillo JD, Contag CH, Barron AE: Efficacy of antimicrobial peptoids against mycobacterium tuberculosis. Antimicrob Agents Ch 2011; 55: 3058-3062.
124. Jena P, Mishra B, Leippe M, Hasilik A, Griffiths G, Sonawane A: Membrane-active antimicrobial peptides and human placental lysosomal extracts are highly active against mycobacteria. Peptides 2011; 32: 881-887.